Aurobindo Pharma arm CuraTeQ gets Health Canada NOC for Bevacizumab biosimilar

Aurobindo Pharma subsidiary CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva, its bevacizumab biosimilar.

A humanised monoclonal antibody, Bevacizumab slows tumor vascular maturation and treats aggregate cancers, including colorectal and lung. The originator merchandise Avastin is marketed by Roche/Genentech.